Departments of Medicine.
Antimicrob Agents Chemother. 2013 Nov;57(11):5717-20. doi: 10.1128/AAC.01236-13. Epub 2013 Aug 19.
To compare the in vitro antibacterial efficacies and resistance profiles of rifampin-based combinations against methicillin-resistant Staphylococcus aureus (MRSA) in a biofilm model, the antibacterial activities of vancomycin, teicoplanin, daptomycin, minocycline, linezolid, fusidic acid, fosfomycin, and tigecycline alone or in combination with rifampin against biofilm-embedded MRSA were measured. The rifampin-resistant mutation frequencies were evaluated. Of the rifampin-based combinations, rifampin enhances the antibacterial activities of and even synergizes with fusidic acid, tigecycline, and, to a lesser extent, linezolid, fosfomycin, and minocycline against biofilm-embedded MRSA. Such combinations with weaker rifampin resistance induction activities may provide a therapeutic advantage in MRSA biofilm-related infections.
为了比较利福平联合用药在生物膜模型中对耐甲氧西林金黄色葡萄球菌(MRSA)的体外抗菌疗效和耐药谱,单独或联合利福平检测了万古霉素、替考拉宁、达托霉素、米诺环素、利奈唑胺、夫西地酸、磷霉素和替加环素对生物膜包裹的 MRSA 的抗菌活性,并评估了利福平耐药突变频率。在利福平联合用药中,利福平增强了甚至与夫西地酸、替加环素、以及在较小程度上与利奈唑胺、磷霉素和米诺环素联合用药对生物膜包裹的 MRSA 的抗菌活性。这些诱导耐药性较弱的联合用药可能在 MRSA 生物膜相关感染中具有治疗优势。